- Conditions
- Childhood CNS Tumor
- Interventions
- SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab
- Genetic · Radiation · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- RECURRENT GLIOBLASTOMA
- Interventions
- SGT-53, Temozolomide
- Genetic · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neoplasm
- Interventions
- SGT-53
- Genetic
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
- Interventions
- SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
- Drug · Radiation
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Carboplatin, Pembrolizumab, Transferrin Receptor-Targeted Liposomal p53 cDNA
- Drug · Biological · Genetic
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- SGT-53, nab-paclitaxel, Gemcitabine
- Genetic · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Neoplasm
- Interventions
- SGT-53, Topotecan, Cyclophosphamide
- Genetic · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas